Approval · Notice of Compliance 1471 · 2000
ADVAIR: Notice of Compliance 1471
Issued October 12, 2000
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1471
- Date
- October 12, 2000
- Company
- Glaxo Wellcome Inc.Mississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: regular treatment of reversible obstructive airways disease, including asthma, in children 4-11 years
- Therapeutic class
- Bronchodilator and corticosteroid for inhalation
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ADVAIR | Not yet assigned | — |
Medicinal ingredients
- FLUTICASONE PROPIONATE 100 MCG per PCK
- SALMETEROL XINAFOATE 50 MCG per PCK